Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning and welcome to our presentation of the third quarter. We'll start with me giving a company update, and Svein Martin Bjørnstad will take over to give a financial update. Just a brief view of our history where you can see a strong record of growth with Svein Martin Bjørnstad. So going into the third quarter and the highlights of the third quarter, we continue to have strong sales this quarter. We are especially happy about bringing Falck Norway on board. Occupational health is an area in which we strongly believe and where we have a good position to grow. There are many large occupational health care providers which we aim to grow with. We have also done good work in bringing on Frelsesarmeen. Frelsesarmeen in Norway. And we continue to have good sales on our AI assistant. Medsum. But I will come back to that. Also, our recent acquisition, InfoSolutions, is developing very well and is going according to plan. InfoSolutions will next year be among our top companies when it comes to the Rule of 40. So that means growth and profit margin. So that acquisition is going very well. And I think the management is doing a great job in that part of our business. Germany is now entering a new phase. I will come back to that. But we are now setting up to rapidly start selling our new product. But I'll come back to that. Looking at growth, we had 29% organic ARR growth and 14% total ARR growth. The 12% organic revenue growth is a bit lower. And it has a lot to do with Germany, which I will come back to; EBITDAC of 21 million in the quarter and a margin of 20%. So, if I start with Medsum. So that is our AI assistant that we built into our software. And what it does at the moment is that it listens in on the conversation between the caregiver, doctor, or physiotherapist, and the patient. And it automatically proposes clinical notes based on that conversation. It saves a lot of time for the caregiver, freeing up time to see more patients. And we are now close to 400 active users at the end of September. We have 300 paying users. So it is growing quite rapidly. And what's really fun to see is that the customers really like this functionality. I think all of us use different types of software where they build in AI systems that do not really do anything useful. Doctors, nurses, and physiotherapists have a lot of administrative tasks to perform for every patient they meet each day. So there's a lot of time spent on basic documentation, which we now can do for them. So it really saves them a lot of time and they really love this type of functionality. We are currently very focused on the product. So that is also good. We will now soon launch more functionality and are updating the entire UX. So we have the AI even more embedded into the experience, ensuring a seamless integration of both UX and AI. So I will show you some pictures of that shortly. We are doing an MDR certification. So, the governing body in Sweden for this type of product has said that these types of solutions need to be certified according to MDR. So that is quite a big project because it is Class IIa, which means that we are spending a couple of million in Q4 to get it done. We are already spending a lot of time preparing all the documentation, conducting tests, and verifying different types of scenarios. So that is an important project going on this year. It does take some time, making it slower to get other functionality out, but over time it will help us because there will be fewer ambient scribes on the market because of this type of regulation. And we are also allowed, after we have done this, to do much more than we are doing today. So that will really be good in general in the rollout of the AI assistant in our software. The aim now is to get as many early adopters in different clinics to start using it. So for most customers, when we have a new customer, it is usually one organization. So one customer can be one clinic, or it can be a larger organization, and so on. And what we are aiming for at the moment is to get many early adopters starting to use it in different clinics. So one or two users in each clinic is what we are aiming for. So that they can then spread the word to all the other professionals working in those clinics. This is really about getting people to start using it to see that it is really useful. Many are a bit skeptical. And also, healthcare is a really slow market. I have never seen technology spread very quickly in this market. And this is the quickest I've seen, I must say, in all my years in this sector. So we are really trying to get many users to start testing it in different clinics so they can talk to their colleagues. And we will then grow within each clinic, each customer, and also with new customers all the time. So yes, looking a little bit at what we're doing with this; this is from Webdoc. So it is our largest product. And sorry for the Swedish, but it is a Swedish product. So it says main content on the left. So that is where you will work. We are looking at the medical records, the calendar, or whatever else is needed. And here on the right is the AI assistant. As it works today, it does not look exactly like this. This is how it will look by around Christmas. But it works like this today. So you are recording the meeting with the patient. Or you can also do what the second option is, which is to dictate, so after the patient has left, you can add some more notes just by speaking them out. Or you can only do dictation if you want to and just talk to Webdoc. It will propose a medical note just as you used to do with a medical secretary. What's coming next is: This functionality. So while you're talking to the patient, we will look at all the administrative tasks you will have to do after the patient has left. So here I am talking with the patient that has pain in the foot. So the first one there, and again, it is a note to check in. So that means this patient is going to go on sick leave. Then the doctor has to fill out a really long form. There is a lot of text there. And if you don't do it properly, they will send it back to you and you have to do it again and so on. So you really want to do that well. But it is really not a fun task and it takes a lot of time. So here we have captured from the conversation that the doctor has told the patient that I will put you on sick leave. I will, and we will book a revisit in four weeks. And I will also send a referral to an orthopedic surgeon, and I will write a prescription for your Naproxen, and all of these things pop up here. That is the easy part. But what we will also do is prefill all these things. So after a visit or during the visit, if you want to, this pops up as you talk, and you can click on these things, which will take you to the right place in the system with basically everything you need already filled in, except for medication, because we are not allowed to do that here. There we can do certain things, but not everything. So this will really save a lot of time for them. And make sure that you just go to the right place at the right time. Everything is prefilled, so you do not have to worry. Our aim is also that you shouldn't even have to wait for the LLM model to work, because we can do this in the background while you say goodbye to the patient. So, I think this will really add a lot of value. We have been discussing it a lot with our customers. And this is the functionality they want to see and the type of work they want to offload. So this is coming around Christmas, and then it will help grow sales even more. We will not increase the price. The price will stay where it is at roughly 750 kroner per user per month. Looking at Germany, it has been going a bit slower than we expected to bring Webcur, our new system, to the market. Even with AI, it still takes a lot of time to really make software that fits the users' needs. But we are getting there. Pilots are happy. The customers we show it to are happy. So we are now preparing to push it really into the market. There has been one big project that has been holding it back somewhat, and that has been the reporting of public patients, but that is almost done now also. So now we're really setting up to push it. But in the meantime, as you can see, our churn in Germany has been quite significant, and that is mostly due to the legacy products. It is only with the old product, and it is usually doctors retiring. And the ones taking over the clinic want the new system rather than the old system, that of Data-AL. So that is why we have quite a big churn that will affect a large part of the entire group. So the churn in the Nordics is really low. And as you can see also, the organic revenue growth in the group, if you take Germany out, is 15%, and the EBITDAC margin of the group is 25% without Germany. That is why we really believe in Germany. It is a really large market. Most customers are on really old on-premise solutions. Nothing close to what we have. And the reason we acquired Data-AL was to really get an organization in place which we can build upon. It is really hard to build a greenfield project with a startup in a new country. I think that is really unwise to do. So it is important to have something to build upon. That is why we acquired Data-AL. And now to really have this push into the market, we have a new CEO in place since September. He has a strong background in sales and marketing within this sector. We have also replaced parts of the sales team, added new salespeople, and changed the product management team to really increase the speed and get to the market quickly. So, we will really start pushing this now in Q4. It will mean in the short term that our costs go up somewhat, but we believe strongly in both the product and the market. And the last point on this slide is a bit interesting. So I mentioned the journey of the Data-AL product. As you all know, our plan was to close that product down eventually and to try to move as many of them as possible to our new product. Once the new product has all the functionality that the old one has. But with the help of our high speed in development, and especially since Data-AL is a product we already have, it is quite easy to work with it using AI to modernize it. So we are also pushing to modernize that product, to decrease churn, and possibly to keep that product alive. We will see. It is a bit early days. It will go to pilot now, but when you have the entire source code, we basically have all the answers to what the customers want, which has been tested together with the customers over many years. It is a really large market. Most customers are on really old on-premise solutions. Nothing close to what we have. And why we acquired Data-AL was to really get an organization in place which we can build upon. It is really hard making Greenfield with a startup in a new country. I think that is really unwise to do. So it is important to have something to build upon. That is why we acquired Data-AL. And now to really have this push into the market, we have a new CEO in place since September. He has a strong background in sales and marketing within this sector. We have also replaced parts of the sales team and also added new salespeople and also changed the product management team to really increase the speed and get to the market quickly. So, we will really start pushing this now in Q4. It will mean in the short term that our costs go up somewhat, but we believe strongly in both the product and the market. And the last point on this slide is a bit interesting. So I mentioned this, the journey of the Data-AL product. As you all know, our plan was to close that product down eventually and to try to move as many of them as possible to our new product. Once the new product has all the functionality that the old one has. But with the help of now that we have such high speed in development, and especially since Data-AL is a product we already have, it is quite easy to work with AI on it to modernize it. So we are doing a push to modernize that product, to decrease churn, and possibly to keep that product alive. We will see. It is a bit early days. It will go on piloting now, but when you have the entire code, we basically have all the answers to what the customers want and which has been tested together with the customers over many years. It is a good foundation for actually modernizing a product with the help of AI. Looking forward. We will continue to grow strongly, especially in the Nordics. We already do. And we will pick up the pace in Germany. We continue to have strong cost control, make sure that a large part of the growth falls down to the bottom line, and we are pushing Webcur into the market. So we look forward to Q4 and next year; with those words, I will hand over to Svein Martin. Thank you. Looking forward. We will continue to grow strongly, especially in the Nordics. We already do. And we will pick up the pace in Germany. We continue to have strong cost control, make sure that a large part of the growth falls down to the bottom line, and we're pushing Webcur into the market. So we look forward to Q4 and next year; with those words, I will hand over to Svein Martin. Thank you.
From the financial side, the Q3 came in strongly. Growth was maintained at a good level and margins continue to improve on an EBITDAC side. So we basically continue to deliver on our plan of profitable growth. As you see here, the contracted ARR was 424 million at the end of the quarter, where 8 million was signed. Not implemented. Contracts. It grew 14% organically. InfoSolutions also added a bit more than 40 million of ARR. InfoSolutions has developed very strongly, as Daniel Öhman mentioned. Both good underlying organic growth. And now after the cost savings, there is good profitability. And then we will implement price increases by the new year. So in the plans for next year, it will be one of the top performing products in the group from a rule of 40 perspective, which is very positive. EBITDA margin is 25% and EBITDAC is 20%. We keep converting most of the extra revenue into profits. And then we also had a net revenue retention of 110%, which is in line with what we normally see. Looking at the P&L, our revenues grew from 82 to 108 million, a 12% organic growth. You see here that in the revenue categories, consulting more than doubled. And that is mainly because InfoSolutions has a slightly different revenue mix than the other parts of the group. Gross margins were slightly diluted from 85% to 84%. The cost base increased slightly on the personnel and opex side. This is mainly driven by the addition of InfoSolutions and also by a lower degree of capitalization than we had the previous year. But on the EBITDAC side, which is the metric we focus on for profitability. It improved from 15% margin to 20%, which was a growth of 75%. And there were no one-offs this quarter either. Then the last point five there on the slide, I want to spend a couple of minutes on, as Q3 is seasonally our strongest quarter. On the margin side, personnel costs are lower because of the holidays. Revenues are also a bit lower, but in total, the effect is positive on the margins, which of course does not carry into Q4, where the cost and revenue is normalized. And then we will also have some extra costs in Q4 related to the MDR certification of Medsum, and we are stepping up the sales and marketing efforts in Germany. Also, it's important to bear in mind when we compare to Q4 last year, it was a very special quarter. So to repeat what I said on that conference call in Q4, we had very high consulting revenues, including a big one-off revenue in Germany. And the positive one-off effect on the cost side related to the grant reduced costs. So I said already on that call last year that it's not something that comes regularly and these effects won't come back in Q4 this year. So the improvements that we see here in Q3 will be smaller in Q4 and Q4 will have a lot of noise in the comparison. But it is important to note that most of this is temporary. The underlying trend here is the one that we see in this quarter. And that does not change. From Q1 next year, the comparison will be cleaner as the temporary costs have been resolved. So we will get back to the big improvements that we have seen over the last few years. Our bridge is where we see the growth. It is more or less in line with what we are used to. The net upsell is strong at 13%, representing 42 million. This is driven by the same factors as normally, as we add more clinics. And at existing customers, our customers have volume growth and we also sell new modules. It's worth mentioning that Capio Norway is an important contributor to this bucket, given that it was onboarded during Q4 last year. It was also a major part of the backlog that you saw in Q3 last year. Medsum is also starting to show up here with now 3 million in ARR and will be an important driver going forward. The next bucket is churn, which is 9 million, 3%, or 2.8%. The Nordics is still below 2%. So? So the German business is contributing a lot to that churn. Unfortunately, we have new customer sales of 13 million, taking the organic growth to 14% for the group and 15% in the Nordics isolated. You see that the backlog is now 8 million. So that was six in Q2. So it has grown quite a bit. And this is because we had a very large backlog compared to normal for Webcur in Q2. And part of that backlog we have kept because there are fewer implementations during the summer. But then we have also added these big contracts that Daniel mentioned for Falck and Frelsesarmeen. So Q3, as it was in Q2, was also a very strong quarter. Actually, on the sales side for the group. So the scalability slide shows our focus and how the business works. So you see that over time, revenues have grown from 245 to 390. It is partly due to acquisitions, but also a very strong organic growth. And then the costs you see below there on the organic side have been basically flat over this period. So in the same period, we have had an EBITDAC improvement of around 100 million. And this is because we have been able to keep that dark blue part flat. We have taken on costs in many places such as AI costs and different roles, but we are taking out costs in other places. So, this is a very important part of that. We have been able to increase our profits so rapidly. Finally, on the cash flow, the third quarter is seasonally weak on the working capital side. You see that the change in working capital was -22 million this year and -21 million last year. It is because we pay out holiday salaries and we do not have any large annual invoicing in this quarter. So, operational cash flow was 5 million, but in the year-to-date figures, you see a better picture of the working capital model that we have. So, the operational cash flow is 74 million and free cash flow after CapEx is 48. It is also quite a bit higher than the EBITDAC, because the working capital is supportive as we charge upfront in the majority of the cases and pay invoices after the period. So a very strong cash flow so far this year; we did not have any changes on the capital allocation. We did not have share buybacks this quarter, but we have repurchased 40 million in the beginning of the year. And the cash position remains at 47 million SEK. So that was all from me. And let's open up for questions.
If you wish to ask a question, please dial the pound key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Frederik Nielsen from Redeye. Please go ahead.
Thank you. Good morning, Daniel and Svein Martin.
Good morning.
Regarding Germany and the initiatives to mitigate in Data-AL. Shown in Data-AL. Should we view that as mainly a short-term initiative, or is there a potential for a long-term shift in strategy in Germany?
Yeah. So, I think there might be potential for a long-term shift. I think in these times, it's important to stay flexible and nimble and not to get stuck in plans. It has nothing to do with our belief in Webcur; it is unchanged, but it is our belief that we can do so much more with our software now. And we know that it is always so difficult to get customers to change. So if we can renew the present product, then that will really make it much easier to keep the customer and start growing with them. So we are testing it. We will see if it works. It seems promising. And because that has always been the most difficult part of developing software. It is not really about writing the code. It is to really understand the customer's needs and show them what you have done. Really change after you talk to them, understand what the different integrators need, understand what the public needs, the regulation needs, and all these needs up to one software, so to speak. And all those needs are what make it quite difficult to develop new software. That's why Webcur is not moving according to plan, really. It is a bit behind, but in a product that you already have, you have solved all those needs. The problem used to be that if you had solved all those needs and then the technology became outdated, there was no way to take all that code and just start transferring it to a new language. It would take so many years. So you do not do that typically. But now with AI, there is potential to renew legacy products much quicker. In a way that wasn't possible before because you have all those needs described in that code and you have solved all those parts. So it is just a matter of moving the code from one language and one architecture to another. So that is what we are testing. I am not saying what we will do strategy-wise, but I think it is worth mentioning. I think it has the potential to lower the churn in Germany and potentially to shift, and maybe we will have two products. It is not as difficult to have two products as it used to be either. Did that answer your question, Frederic?
Yeah, I think it was a clear answer. Thank you. Obviously, you have an impressive pace in the Medsum area currently. Could you share your expectations for next year? Do you think you can accelerate the pace in net new users in absolute terms further?
Yeah. I am very close to this product, so I am extremely optimistic about it. But I think that healthcare is really slow. I have mentioned this many times. I think it is worth mentioning again. So all the doctors and nurses, and keep in mind we are in Sweden, so remember that. But this goes for a large part of Europe. All the doctors, nurses, and physiotherapists are educated in the public system. They have lived a large part of their lives in the public system before going private. So they work in an environment that has very little change. They work in basically the same way as they did 20 years ago. And this means that they are not used to change. They are also trained not to make mistakes. You can be reported if you make a mistake; you can lose your license to provide care as a doctor or a nurse if you commit mistakes. So it is. Healthcare is very slow to change by nature, and that might be good in certain ways, but when driving a new technology, that is really a hinder. But I expect over time that it will be a really big product. If you look at the US, to me most statistics show that 70 to 80% of all outpatient visits in the US use ambient scribes. So in the US, you have much more commercial healthcare. So it is much more pushed towards efficiency and there is much, much less regulation. So you can just give the customer this type of functionality. So in Europe, it's obviously moving way slower. I think that our expectation is that today 5 to 10% of our users use this type of technology, either from us or from a competitor or a partner in some cases. So, I think it will not go as quickly as it should, because this saves so much time when we talk to users. They already say they save one hour per day or they save half of their administration; these are the types of things they say. And with the new functionality that we have coming out with even better integration into the software, we will save even more time and make the user experience even better. So it can go quite quickly, but we don't see it yet. I would say, but over time, I think this will be used by most users in our software.
I see. Great. Could you give us an update about your progression in Region Stockholm? Is the solid momentum still there, and could a potentially less left-leaning new regional government be a positive factor going forward?
Can it be a positive factor or less left-leaning, okay? Sorry.
Yeah, exactly. Yeah.
Yeah, yeah. So, yeah. Region Stockholm is moving forward. Well, we have finalized e-referrals going in, so we have a number of clinics that started during the summer, which has our e-referral solution. Referrals going out will do end-to-end tests. I think it is next week. So then we can launch that to our customers as well. So Stockholm is going well. It is, as you know, by far the largest market, and if the new regional government is less left-leaning, that could be a positive factor. Yes, it will probably be positive. But I think it is likely because the region will be dependent on Centerpartiet and what they have done so far. This coalition has not worked very well. So I think that they have destroyed quite a lot of well-functioning private care. So I think that has probably come to an end. I think they feel that themselves; actually, usually when a region changes political leadership, I mean, I have been in this industry since 2006. Usually when you change color, it doesn't really change that much for the caregiver. It is usually just a lot of talk before the election, and then nothing happens. The right usually implements more reforms, while the left typically does not prioritize private providers as much. The last election. So, the last four years, Stockholm has behaved a bit differently. I think it is because all the politicians on the left side were new. So they hadn't been in power before because it was eight years since the last time. So I think that is why they did a lot of naive things, which I don't think they will repeat, but they will have the same language before the election. And also after, as they usually have, but usually very little happens. And I expect that to be the case when it comes to changes for private care providers.
Okay. I see, and one last question from me. Could you give us an update on the surgery offering?
Yeah. So, surgery is a great module. We are showing it to a lot of potential customers at the moment. We also have a lot of customers using it. Those are still the really big customers. So they come in. It is quite a long process to convince them to change. We are in discussions with a number of them. And so far this year we have had quite a few big, really big units changing to Webcur. We have a large number of small ones and small startups and so on. And then we grow with them. So that is fine. But we are looking forward to getting some bigger ones also into our books. But it is a well-functioning module, and it is well-appreciated by the users who use it. And we will continue to grow with that functionality.
I see. That is all. Thank you very much.
Thank you.
The next question comes from Elvin Rohleder from DNB Carnegie. Please go ahead.
Yes. Good morning, Daniel and Martin. I hope you are well. I have a couple of questions from my side as well. Perhaps beginning with Webdoc and the more AI-integrated workflow. Can you tell us a little about how these features have been received in pilots? And is this something you expect to gain broad-based usage amongst clinics? It is similar to Medsum in the beginning. It will be more of early adopters before gaining the bigger end of the tail. And then I do not know if it was my line that was bad, but I believe you mentioned price. Can you just reiterate what you said regarding the economics behind it? Will there be an increase in price based on this, or will you bake these feature upgrades into yearly price adjustments?
Yeah. So. Yes, this functionality, the new one where we have multiple agent loops looking into the conversation and finding actions. And then from the actions we trigger, for example, the second node and so on, that functionality is not yet completed. I think we will just pilot it for about a week and then we will roll it out because it works well in our internal testing, and we have done the really messy part with handling medical notes. The medical notes are difficult because all or many of our users use completely different structures, words, and fields; for example, if they have a field called status, what each user wants in that field is very different, but they want it done their way. So, the normal thing we do is really, really messy. So for each user, the system does not train, but it learns how that user wants their medical notes structured when it comes to sick leaves and other documentation; they simply want it to pass. We expect that to be much easier. So we will just add those functionalities as we go. We will also add normal speech-to-text functionality to the entire system. So we will just add functions. So far, the COGS for these types of solutions are a bit higher than in the normal case, but they are still not high. It allows us to maintain good margins on the product. We charge 750 kroner per user a month, and we aim to continue to charge 750 per user, even with the new functionality. And it will be included. So, we use these new features to drive up demand. It will be really like you have your personal secretary doing everything for you. And it will be much quicker than if you use your secretary. It will be used to grow quicker because 750 kronor per user almost doubles our revenue per user on average. It is a great business for us to add this functionality. So we just want to expand quickly. We are incurring significant costs just to get it out there. We just want as many clinics as possible to test it. It does not have to be many users in each clinic, but many clinics to test it. We actually prefer maybe one or two users who are really interested in it. And then they can spread the word internally because usually the ones that start using it get very positive and then they bring others on board. So, at the moment, I will focus on sales. And this is just to talk to as many clinics as possible to start getting one test user, so to speak.
Okay, perfect. Thank you. Maybe moving on a bit to Germany. And I guess related to what you were mentioning on the modernization potential for the legacy Data-AL products. Is this something that you are also seeing more incumbents in Germany pursuing, given that they are able to use AI to modernize their products? Or are they still lagging, or do you expect their products to become better? And perhaps that new customer sales for Webcur could become a bit more difficult than perhaps initially perceived if they are able to modernize the products, or how do you view that?
Yeah. That is a really interesting point, and I think that is where we need to keep a very open mind. What we have been worrying about for the last couple of years is that AI will make it easier for someone to launch completely new products and compete with us, for example. That is why we have made acquisitions to strengthen our position. We have increased our development pace so that we maintain the same distance between the competition and us. And then we have seen it, as we start moving much, much faster than before. We are moving much faster than before. And the competition, the larger legacy systems, as of yet, they still aren't really moving as we see it. So that is how we have been looking at it so far. Now, given that customers really don't like to change, there is the potential that we will see that older software can be modernized much more cheaply. It used to be that you simply let them die. I think that if you've gone too far down that route, it might be difficult to turn back. But there is a risk for that. But it also seems to me like the really big players with legacy systems don't really seem to get going as of yet, at least, but we'll see. It is difficult to say. I think that what we will see in general is that the software usage will be much higher than before. And as we sell complex software with a lot of functionality, we used to have a lot of different wishes. It means that we will need to have our software much more adapted to each user's and each customer's needs. I think that in a couple of years, our software will look very different depending on what type of user you are, what type of care you give, and so on. So that is where I expect it to go. I think that our customers are fine spending 1% to 2% of their revenue on EHR systems. And if we can help them help more patients, it really pays for itself. So I expect a lot of the pain to disappear in health care, thanks to systems like ours going forward at a much higher pace. But I think it's very important that we stay nimble, open to not getting stuck in strategies, and take the opportunities that are out there now.
Uh, great. Thank you. The final question from me. Perhaps relating a bit to costs, I believe in Q2, you mentioned the 2 million in MDR costs during H2. Has any of that been affected here in Q3, or will all of that, or another amount, come in Q4? And can you provide some color on the expected costs for the increased sales and marketing efforts in Germany?
Yes. Related to MDR, we have done some preparatory work in Q3, but the majority of the cost will come in the next quarter. Um, yeah. And then on the sales and marketing side, it's a mix. We have added quite a few salespeople, around three or four, that did not really have an effect on the costs in this quarter, but will have in the next. And then we also do some. More one-off related initiatives will drive costs. So in total, around 3 to 4 million in extra costs in the upcoming quarter compared to this one, I would say.
Okay, great. Thank you so much, guys. I will get back in the queue. Sure.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Viktor Lindstrom from SR-One Markets. Please go ahead.
Hi. Thanks for taking my questions. I have a few questions. So, starting out, is the contribution from new sales to organic ARR growth a bit lower compared to previous quarters? But we say that this is mostly timing effects given the contracted ARR backlog.
Um, yes. It is a mix and is a bit due to the fact that we had a few large new customers start in Q3 last year, so they drop out. And then we have big new contracts such as I mentioned, Volvo, for example, that get put in the upsell bucket because we had a very small part of their business from before. I would say that the sales performance has been very strong so far this year, particularly in both Q2 and Q3. But I would say it is a bit of a categorization as well, given that we sign a lot of clinics that we have an existing customer relationship with in the chain or the group. So, that is the main reason.
Okay. And then apart from the new signed contracts, do you expect the majority of the backlog to be implemented by Q4, or should we expect that to have a larger contribution in 2027 instead?
Yes, the backlog is mainly composed of Falck, Frelsesarmeen, and then Webcur customers. The plan is to implement almost all the Webcur part within this year, but Falck and Frelsesarmeen will be, with Falck being next year and Frelsesarmeen split between this year and next year. So, the majority of the backlog will be implemented in Q4.
Right. Thanks. And then, I have a question on the gross margin. It was slightly higher than in Q2. Despite that, InfoSolutions contributed for only one month. So, I am curious, could you quantify the gross margin that InfoSolutions currently operates at?
Uh, yes. So they have a gross margin. That is around 70% approximately. So a bit lower than the group. But then we also have InfoSolutions, which had quite some revenues from Webdoc, which now after we consolidate, means that revenues are eliminated from revenues from InfoSolutions and COGS on Webdoc. So that has a positive effect on the margin. So it does not dilute that much.
All right, I guess. I mean, with the coming price hikes that we will also see. You will also see additional support from the top line.
Yes. But it is important to note on the price increases for InfoSolutions, we do it on the ARR, like we said in Q2. So InfoSolutions has a bit higher non-recurring revenues than the rest of the group and there, we don't see that price increase.
No, I think so. All right. Thanks. That was all for me.
Thank you.
There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.
Okay. We have a few questions here in the chat. First one from Marcus. What is the percentage of users paying for the AI functions at present out of the total users? Um, yeah. As we illustrated on the slide, we only have about 300 users paying for it. To date, in the EHR systems, we have a lot of users, maybe around 30,000 to 40,000 active users in total. So, the potential is big, but of course not all of them will use this functionality, though there is potential to scale. And there are quite a few of them that are using these types of solutions. So far. Then from Jacob, can you share some more on the customer perspective of Medsum? What is the quality of the transcripts now compared to the first-generation products you implemented? When you look at cost savings for your customers, what is the payback time for your average client?
Yeah. So with the first generation of Medsum, we tried to avoid using US-owned clouds, even if they were located in Europe. So then, we used open source models. At that point in time, we could not get the quality where we wanted it at all, or where the customer demanded. So then, it was quite bad compared to now. But having said that, you have to be like 99% right. If they have to change more than maybe 1 or 2 words, they do not like it well enough. It is really easy to develop a product. To reach a point where it seems like the product is really good. And then when you bring it to users, they struggle. But I just want to use this one. I want to use that one. And many users. So doctors, for example. Talk to the patient. They use language the patient understands. But then in the medical records they want to use more of the correct medical terms. So there is a lot of work in ensuring that we do not use the colloquial words used in the conversation. We use the medical terms and ensure that we do not use the incorrect medical terms. So it is really a lot of work at the margin to get it really good. But out of the box, they are really good, but it's not good enough. The difference is not huge. But what we have is much, much more personalization. So it fits how you want it done. So that's the big difference. The payback time for them is short. So if they save an hour per day at the moment. That will easily give them the time to see one extra patient. One extra patient is on average, I would say, around 1,000 kroner of revenue. So, the cost for the solution is 750 kroner per month. Most doctors do not see patients five days a week, but rather four days a week. So then you have 4,000 per week in extra revenue. So 16,000 per month roughly. It costs 750. So the payback is really easy. But healthcare is really slow to change, and that is the problem. And we cannot price it according to the value we provide them because there are other solutions out there. We have a really strong position because it is fully built into the system and we have access to information that the external ones do not have. So our solution is and will be better for most users. But anyway, we wanted to grow really quickly and that is what we price it for.
The next one is that R&D headcount decreased during the quarter. This is related to the restructuring. InfoSolutions. Yes, it does. Then one from Yannick. Sorry if I missed your comments regarding costs in Q4, but what will be the extra costs you expect to have for MDR professional services and IT services? How much of these will be recurring? To ask more simply, what are your expectations for the recurring cost base from Q1 next year? Um, so, um. It is a mix regarding the increased cost and it is also related to the comparison, as I mentioned, where we had a bit of reduced one-off cost last year. It is a tough comparable, but out of the sales and marketing costs, the personnel I mentioned will naturally come back. So that will increase the cost base by a couple of million in Q1. But other than that, it is mostly temporary effects. Final question we have gotten in the chat is, good morning. I noticed Alaris has taken over several small target clinics from September and onwards. Have those revenues gone live for you yet?
Yeah. Good. I think these are probably eye clinics you're referring to. So we have a number of clinics for which they won the contracts in Stockholm, and those are the ones that have started using e-referrals. So we had to really push, because Stockholm closed down their choice around eye surgery. And then it went on tender instead. And so, a lot of present clinics had to close down or change what they did. And then new clinics started. And that is great for us. Then we just need to win the competition. We don't need to convince someone to change systems. So that is why Aleris and some others said that they want to use Webdoc and would love it if we could get it working by that point in time, because there will be a lot of referrals coming in. That is what we really pushed for in Q2 in development to get it out and tested. And especially, Stockholm was really great in helping us in that. So, they got up and running. So, a couple of clinics have gone live. But that being said, I don't think there has been significant revenue from this in Q3. The reason is that I do not remember exactly the date when they started seeing patients. Referrals started coming in during the summer. But I think they started seeing patients at the end of Q3 or early in Q4.
It is part of the backlog as well, some of those clinics.
Yeah. So they haven't started yet. Yeah.
That was the final one.
Okay, then. Thank you all for today. And have a good day. Just reach out if you have any more questions. We are always available. Thank you.



















